The FDA signaled escalating enforcement, and on April 30, 2026, it proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list - the mechanism that governs which substances large-scale compounders may use - with a public comment period open through June 29, 2026
Studies have shown that Rybelsus, when used as part of a comprehensive diabetes management plan, can lead to significant reductions in HbA1c, with some patients achieving levels below the diabetes threshold
We thank Joanna Loizou and Anna Schrempf for providing p53 mutant human TERT-immortalized retinal pigment epithelial 1 (RPE1) cells
This requirement can be looked at as a positive or a negative - on the positive side, Piper isnt prescribing GLP-1 medications to just anyone, regardless of whether they truly need it or not